October 3, 2017
FDA accepts sNDA filing for Allergan’s pneumonia drug
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Allergan’s Avycaz (ceftazidime and avibactam) for priority review.